

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

CESSATION OF HONORARY SCIENTIFIC ADVISOR

This announcement is made by Sirnaomics Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated December 29, 2022, January 12, 2023, July 8, 2024, December 13, 2024, January 14, 2025 and March 18, 2025 (collectively, “**Announcements**”). Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

The board (the “**Board**”) of directors of the Group hereby announces that Dr. Yang Lu (*alias* Patrick Lu) (“**Dr. Lu**”) ceased to be the Honorary Scientific Advisor of the Group with effect from April 23, 2025. The Board has further resolved that Dr. Lu ceased (i) all positions of Sirnaomics Biopharmaceuticals (Guangzhou) Co., Ltd. and Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. with effect from April 23, 2025 and (ii) all positions of Sirnaomics, Inc. with effect from May 22, 2025 (collectively, the “**Cessation**”). After the Cessation, Dr. Lu will not hold any position within the Group. The Cessation allows the new management team room to focus its efforts on stringent internal control measures and on regulatory compliance.

The Board considers that the Cessation would not have any material adverse effect on the business operations of the Group. Save as disclosed above, to the best of the Directors' knowledge, information and belief, there is no other material matter relating to the Cessation that needs to be brought to the attention of the shareholders of the Company.

By order of the Board

Sirnaomics Ltd.

Monin Ung

Chairlady and Independent Non-Executive Director

Hong Kong, April 23, 2025

As at the date of this announcement, the Board comprises Dr. Poon Hung Fai as executive Director, Mr. Jiankang Zhang as non-executive Director, and Ms. Monin Ung, Dr. Cheung Hoi Yu and Mr. Wong Yu Shan Eugene as independent non-executive Directors.